Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Decline in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 100,300 shares, a drop of 17.2% from the March 15th total of 121,200 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 203,900 shares, the days-to-cover ratio is presently 0.5 days.

Appili Therapeutics Trading Down 9.7 %

APLIF stock opened at $0.02 on Tuesday. The stock has a market capitalization of $2.72 million, a P/E ratio of -1.12 and a beta of -0.54. The firm has a 50-day moving average price of $0.02 and a 200-day moving average price of $0.02. Appili Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.04.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.